A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs AutoSynVax (Primary) ; QS 21
- Indications Cancer
- Focus Adverse reactions
- Sponsors Agenus
- 07 Nov 2017 According to an Agenus media release, immunological readouts expected in patients with advanced malignancies in 4Q 2017.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to an Agenus Inc. media release.
- 04 May 2017 According to an Agenus Inc. media release, readouts for immunogenicity expected in patients with advanced malignancies in H2 2017.